Close Menu

UMass

NEW YORK (GenomeWeb News) – A new study is adding heft to the notion that cytoskeletal pathway alterations can spur amyotrophic lateral sclerosis, or ALS, commonly known as Lou Gehrig's Disease.

Silence Therapeutics said this week that it plans to raise as much as £5.7 million ($8.8 million) through the issuance of up to around 940 million new ordinary shares.

Roughly one week after a US District Court rejected the efforts of University of Massachusetts officials to have an intellectual property lawsuit filed against them dismissed, the UMass defendants have filed an appeal with a federal court to re-examine the issue.

A Massachusetts District Court this week denied motions to dismiss an intellectual property-ownership lawsuit filed by the University of Utah against Alnylam Pharmaceuticals and several University of Massachusetts officials, among others, telling the defendants that they have not

The University of Utah last week fired back at a bid by University of Massachusetts officials to have an RNAi technology intellectual property lawsuit dismissed, arguing that the court hearing the case — and not the US Supreme Court, as the officials contend — is the appropriate

Silence Therapeutics has scored a victory in its efforts to defend its intellectual property estate, announcing this week that the US Patent and Trademark Office has upheld the validity of four patents related to the design of RNAi molecules.

Pages

Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.